>Drug makers have no incentive to see them. Drug makers aren't the people looking, the regulators are. Here in the UK, the medicines regulator operates an ope

>Drug makers have no incentive to see them. Drug makers aren't the people looking, the regulators are. Here in the UK, the medicines regulator operates an open reporting system for adverse drug effects. Any patient or healthcare professional can make a report of an adverse drug event, no matter how minor. The collected data is publicly available in anonymised summary form. 110 countries share detailed reports of adverse drug events through the WHO VigiBase, which is monitored for risk signals by a dedicated team at the Uppsala Monitoring Centre. Potential safety problems are then fed back to national regulators. All of this reporting apparatus was put in place after the thalidomide disaster. It's designed as an extremely sensitive early-warning system to detect subtle or rare adverse events. For the most part, it works. I'd suggest taking a look at the WHO Pharmaceuticals Newsletter, which shows how this information sharing works in practice. https://yellowcard.mhra.gov.uk/ https://yellowcard.mhra.gov.uk/ https://www.who-umc.org/vigibase/vigibase/ https://www.who-umc.org/vigibase/vigibase/ http://www.who.int/medicines/publications/WHO-Pharmaceuticals_Newsletter_No1-2018.pdf http://www.who.int/medicines/publications/WHO-Pharmaceutical...